
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech has exhibited robust growth in revenue, particularly in its surgical soft tissue repair products, which saw an increase of 24% year-over-year to $23.4 million, largely driven by heightened demand for CellerateRX Surgical. Furthermore, the company's strategy to expand its distribution network and healthcare facility partnerships is expected to bolster ongoing revenue generation, as evidenced by a significant 28% year-on-year growth in soft tissue repair product revenues to $22.7 million. The anticipated profitability of continuing operations in the third quarter of 2025 further enhances the positive outlook on the company's financial performance and market position.
Bears say
Sanara MedTech Inc demonstrated net revenue of $26.3 million, reflecting a 21.5% year-over-year growth, which fell short of projections by $0.4 million. Key concerns impacting the company's outlook include risks related to lower-than-anticipated revenue growth, challenges in acquiring new customers, delays in launching products or services, and potential dilution risks. Additionally, the company has experienced a significant reduction in its EV/Revenue multiple from 4.3x to 3.0x following the exclusion of telehealth from its business operations.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares